Skip to content

Integra NeuroSciences Announces Launch of Camino® Single Parameter Monitor in Europe and Other International Markets


<< Back

Press Release

Sep 24, 2002

Integra NeuroSciences Announces Launch of Camino® Single Parameter Monitor in Europe and Other International Markets

Integra NeuroSciences Announces Launch of Camino® Single Parameter Monitor in Europe and Other International Markets

Plainsboro, NJ / September 24, 2002/ -- Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that Integra NeuroSciences has launched the Camino&amp;reg; Single Parameter Monitor ("SPM-1") for the measurement of intracranial pressure into Europe and certain other international markets. The SPM-1 product provides Integra's international customers with a low cost alternative to the Camino Multi Parameter Monitor, which measures intracranial pressure and temperature and displays calculated cerebral perfusion pressure. The SPM-1 is used in conjunction with Integra's existing line of fiber optic-based Camino catheters.

Intracranial pressure measurement is necessary to accurately determine cerebral perfusion pressure, a key element in maintaining adequate cerebral blood flow for the delivery of oxygen and metabolites to the brain. Advanced monitoring systems like the fiber optic-based Camino products are an accurate and reliable means for monitoring intracranial pressure at the source, which eliminates the leveling and de-bubbling associated with fluid-filled systems.

"The launch of the SPM-1 product is an exciting opportunity for our international sales team because of its low cost and the familiarity of the Camino name," remarked Deborah Leonetti, Vice President of Marketing. "Many of our international customers are looking for a low cost system for the measurement of intracranial pressure and do not routinely monitor intracranial temperature. The launch of the SPM-1 product shows Integra's continued commitment to meet our customers' needs through the introduction of innovative, new products."

The SPM-1 product is being featured to Integra's international distributors at the annual meeting of the Congress of Neurological Surgeons in Philadelphia this week. Initial launch activities for the product began at Integra's European sales meeting in France last week.

Integra NeuroSciences designs, manufactures and sells implants, instruments and monitors used in neurosurgery and intensive care units, primarily for the treatment of neurological trauma and surgery. Integra NeuroSciences' products are sold through a direct sales force in the United States, the United Kingdom, France, Germany and Belgium and through specialized neurosurgical distributors and dealers in the rest of the world.

Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. Integra has approximately 750 permanent employees. Please feel free to visit Integra's website at (http://www.integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the Company's expectations for market acceptance of the Camino Single Parameter Monitor. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, pricing for the Camino Single Parameter Monitor product may affect market acceptance of the product. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2001 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation

Contacts:
Integra LifeSciences Holdings Corporation
John B. Henneman, III
Senior Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@integra-ls.com

John Bostjancic
Senior Director of Finance
(609) 936-2239
jbostjancic@integra-ls.com